Navigation Links
Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering
Date:1/15/2014

LAWRENCEVILLE, N.J., Jan. 15, 2014 /PRNewswire/ -- Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $15 million of the Company's common stock in an at-the-market registered direct offering, led by a dedicated health care fund.

The Company entered into definitive purchase agreements with these investors pursuant to which the Company agreed to sell an aggregate of 3,603,603 shares of its common stock at a per share price of $4.1625.  Additionally, for each share of common stock purchased, investors will receive a Series A Warrant to purchase one-quarter of a share of our common stock at an exercise price of $4.10 per share, which shall be exercisable immediately and expire five years from the date of issuance, and a Series B Warrant to purchase one-quarter of a share of our common stock at an exercise price of $4.10 per share, which shall be exercisable immediately and expire one year from the date of issuance. The closing of the offering is expected to take place on or about January 21, 2014, subject to the satisfaction of customary closing conditions.

The estimated net proceeds to the Company from the offering are expected to be approximately $13.8 million.  With the net proceeds from this offering, the Company projects to have an unaudited cash and investment balance of approximately $57 million.  The Company intends to use the net proceeds from this offering for general corporate purposes.

H.C. Wainwright & Co., LLC  acted as exclusive placement agent in connection with the offering.

A shelf registration statement (File No. 333-183286) relating to the shares issued in the offering has been filed with and declared effective by the Securities and Exchange Commission (the "SEC").  A prospectus supplement relating to the offering will be filed by the Company with the SEC.  Copies of the prospectus supplement, together with the accompanying prospectus, can be obtained at the SEC's website at http://www.sec.gov, from request at H.C. Wainwright & Co., LLC by e-mailing placements@hcwco.com, or from Celsion Corporation, 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648, Attention: Chief Financial Officer.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company in this offering. There shall not be any offer, solicitation of an offer to buy, or sale of securities in any state or jurisdiction in which such an offering, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  Any offering will be made only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. 

Additional Information:

Statements made in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, regarding, but not limited to, the amount and use of proceeds the Company expects to receive from the offering and the closing of the offering. Forward-looking statements can be identified by the use of words such as "may," "will," "plan," "should," "expect," "anticipate," "estimate," "continue," or comparable terminology. Such forward-looking statements are inherently subject to certain risks, trends and uncertainties, many of which the Company cannot predict with accuracy and some of which the Company might not even anticipate, and involve factors that may cause actual results to differ materially from those projected or suggested. Readers are cautioned not to place undue reliance on these forward-looking statements and are advised to consider the factors listed above together with the additional factors under the heading "Forward-Looking Statements" and "Risk Factors" in the Company's Annual Reports on Form 10-K, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company assumes no obligation to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Senior Vice President – Chief Financial Officer &
Corporate Secretary
609-482-2455
jchurch@celsion.com


'/>"/>
SOURCE Celsion Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials at the 2013 San Antonio Breast Cancer Conference
2. Celsion Corporation Announces Strategic Loan Facility
3. Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update
4. Celsion Corporation to Hold Third Quarter 2013 Financial Results Conference Call on Tuesday, November 12, 2013
5. Celsion Corporation Announces Combined Clinical Data from Two Phase I Trials to be Presented at the 2013 San Antonio Breast Cancer Conference
6. Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update
7. Celsion Corporation to Hold Second Quarter 2013 Financial Results Conference Call on Thursday, August 8, 2013
8. Celsion Corporation Issues Statement Regarding Misleading Blog Entry
9. Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update
10. Celsion Corporation to Hold Year-End 2012 Financial Results Conference Call On Monday, March 18, 2013
11. Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... 22, 2017 Research and Markets has ... Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, By ... ... is forecasted to grow at a CAGR of 5.33% during 2016-2021 ... of infectious diseases along with surging demand of digital thermometer. Apart ...
(Date:2/22/2017)... -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company ... field of urology, today announced the expansion of its ... from 35 currently, a 20% increase in the company,s ... is being driven by the increasing growth of Natesto, ... acceptance of Natesto,s unique product profile and clinical benefits. ...
(Date:2/22/2017)...  CVS Pharmacy is the first national retail pharmacy ... (PHO), the primary source of artificial trans fats in ... products. The retailer now offers over 600 exclusive snack ... fats. This comes a year and a half ahead of ... for processed foods to be reformulated without artificial trans ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... A product of digesting a micronutrient ... a heart-protective benefit from eating soy foods, while others do not, a University of ... able to produce equol—a substance made by some types of “good” gut bacteria when ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued to steadily ... the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also ... the benefits of corn and grains, value of raw and organic diets, and the ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a recent ... the patient context (age, illness and life choices) should be dissociated from medical ... In addition, all too often, studies regarding health system performance in ...
(Date:2/21/2017)... Okla. (PRWEB) , ... February 21, 2017 , ... ... new Choctaw Nation Regional Medical Clinic in Durant, Oklahoma, on Feb. 21. , ... by clinic tours for community members, clinic employees, the construction team and tribal ...
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who have ... related to surgery, treatment, therapy and management. Regular exercise in proper environments has ... life despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a dynamic ...
Breaking Medicine News(10 mins):